SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-042513
Filing Date
2024-04-02
Accepted
2024-04-02 16:15:19
Documents
14
Period of Report
2024-04-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2410454d1_8k.htm   iXBRL 8-K 25659
2 EXHIBIT 1.1 tm2410454d1_ex1-1.htm EX-1.1 20166
  Complete submission text file 0001104659-24-042513.txt   224573

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcli-20240402.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcli-20240402_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcli-20240402_pre.xml EX-101.PRE 22373
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2410454d1_8k_htm.xml XML 3622
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

IRS No.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36641 | Film No.: 24814377
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)